Clinical trial
Topotecan and Thalidomide in Treating Patients With Recurrent or Refractory…
NCT00014443 · Rush University Medical Center, Other · Terminated
Key facts
| NCT number | NCT00014443 |
|---|---|
| Title | Topotecan and Thalidomide in Treating Patients With Recurrent or Refractory Malignant Glioma |
| Official title | A Pilot Study Of Hycamtin (Topotecan) And Thalomid (Thalidomide) In Patients With Recurrent Malignant Gliomas |
| Lead sponsor | Rush University Medical Center, Other |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Brain and Central Nervous System Tumors |
| Intervention type | Drug |
| Interventions | thalidomide, topotecan hydrochloride |
| Enrollment | 5 |
| Start date | Aug 1, 2000 |
| Primary completion | Aug 1, 2003 |
| Completion | Dec 1, 2003 |
| First posted | Jan 27, 2003 |
| Last update posted | Jan 9, 2023 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: